Phase 1 N=4 Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Rubeosis Iridis · Proliferative Diabetic Retinopathy
Primary: Adverse Event (AE) — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
N/A N=7 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
Neovascular Glaucoma
Primary: Incidence of Adverse Events — 3; 4 Participants
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 2 N=26 Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Primary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
Phase 2 N=8 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Proliferative Diabetic Retinopathy
Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…
Phase 4 N=49 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
Phase 2 N=12 Aflibercept Injection for Proliferative Diabetic Retinopathy
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Phase 4 N=30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
Phase 3 N=309 Effect of Ruboxistaurin on Clinically Significant Macular Edema
Diabetic Macular Edema
Primary: Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48 — 3.4; 2.2 percent of participants — p=0.724
Phase 4 N=30 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
Diabetic Macular Edema
Primary: Reduction in Macular Edema — 15; 8; 4 Participants
Phase 1 N=2 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
Nonarteritic Anterior Ischemic Optic Neuropathy
Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart
Phase 4 N=28 Intraoperative Floppy Iris Syndrome
Cataract · Floppy Iris Syndrome
Primary: Corneal Endothelial Cell Loss — 9.85; -3.68 Percent change
Phase 3 N=731 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
Diabetic Retinopathy
Primary: Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME) — 1.72; 1.69 months per participant — p=0.969
Phase 2 N=44 Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
Rhegmatogenous Macula-off Retinal Detachment
Primary: Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 6.7; 6.7; 0 Percentage of Patients
Phase 2 N=109 Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
Diabetic Retinopathy
Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants
Phase 2 N=70 Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients
Phase 2 N=12 REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Macular Edema · Branch Retinal Vein Occlusion
Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Phase 3 N=66 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events
Phase 3 N=295 Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
Phase 3 N=261 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Vitreous Hemorrhage · Proliferative Diabetic Retinopathy
Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37
Phase 2 N=43 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants
Phase 1 N=6 Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Uveitic Cystoid Macular Edema
Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015